OncoMatch/Clinical Trials/NCT06917079
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Is NCT06917079 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments for non-small cell lung cancer.
Treatment: BBO-11818 · Pembrolizumab · Platinum chemotherapy (cisplatin or carboplatin) · Pemetrexed · Cetuximab · mFOLFOX6 · BBO-10203 · mFOLFIRINOX · Gemcitabine · Nab-paclitaxel — A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Pancreatic Cancer
Colorectal Cancer
Tumor Agnostic
Biomarker criteria
Required: KRAS g12a
Required: KRAS g12c
Required: KRAS g12d
Required: KRAS g12s
Required: KRAS g12v
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The Angeles Clinic and Research Institute - West Los Angeles Office · Los Angeles, California
- University of California Davis · Sacramento, California
- University of California San Diego Moores Cancer Center · San Diego, California
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center · San Francisco, California
- Yale University · New Haven, Connecticut
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06917079 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require KRAS?
Yes, KRAS g12a is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS g12c is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS g12d is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify